Stock analysts at BMO Capital Markets started coverage on shares of Audentes Therapeutics (NASDAQ:BOLD) in a research note issued on Tuesday, MarketBeat reports. The brokerage set an “outperform” rating and a $35.00 price target on the biotechnology company’s stock. BMO Capital Markets’ target price would indicate a potential upside of 26.49% from the stock’s current price.

A number of other research firms have also recently commented on BOLD. ValuEngine cut shares of Audentes Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday. Raymond James Financial started coverage on shares of Audentes Therapeutics in a research report on Thursday, October 12th. They issued a “market perform” rating for the company. Zacks Investment Research cut shares of Audentes Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, November 17th. Bank of America reissued a “buy” rating and issued a $33.00 price objective (up from $23.00) on shares of Audentes Therapeutics in a research report on Friday, September 22nd. Finally, Leerink Swann reissued an “outperform” rating and issued a $29.00 price objective (up from $22.00) on shares of Audentes Therapeutics in a research report on Wednesday, November 15th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of $28.29.

Audentes Therapeutics (NASDAQ BOLD) traded down $0.71 during mid-day trading on Tuesday, hitting $27.67. 200,600 shares of the company were exchanged, compared to its average volume of 148,162. Audentes Therapeutics has a 52-week low of $13.90 and a 52-week high of $33.43.

Audentes Therapeutics (NASDAQ:BOLD) last released its quarterly earnings results on Tuesday, November 14th. The biotechnology company reported ($0.88) EPS for the quarter, hitting analysts’ consensus estimates of ($0.88). analysts predict that Audentes Therapeutics will post -3.52 earnings per share for the current year.

In other news, major shareholder Orbimed Advisors Llc sold 672,000 shares of the company’s stock in a transaction that occurred on Friday, September 29th. The shares were sold at an average price of $28.25, for a total value of $18,984,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP David Nagler sold 3,750 shares of the company’s stock in a transaction that occurred on Friday, September 15th. The stock was sold at an average price of $25.00, for a total transaction of $93,750.00. Following the completion of the sale, the senior vice president now directly owns 3,750 shares of the company’s stock, valued at approximately $93,750. The disclosure for this sale can be found here. Over the last three months, insiders sold 758,500 shares of company stock valued at $21,340,610. 47.30% of the stock is owned by corporate insiders.

Institutional investors and hedge funds have recently made changes to their positions in the company. SG Americas Securities LLC purchased a new stake in shares of Audentes Therapeutics in the 3rd quarter worth approximately $143,000. Nationwide Fund Advisors lifted its position in shares of Audentes Therapeutics by 288.9% in the 2nd quarter. Nationwide Fund Advisors now owns 8,594 shares of the biotechnology company’s stock worth $164,000 after purchasing an additional 6,384 shares during the period. State of Wisconsin Investment Board purchased a new stake in shares of Audentes Therapeutics in the 2nd quarter worth approximately $210,000. Rhumbline Advisers purchased a new stake in shares of Audentes Therapeutics in the 2nd quarter worth approximately $252,000. Finally, Virtu KCG Holdings LLC purchased a new stake in shares of Audentes Therapeutics in the 2nd quarter worth approximately $257,000. 78.99% of the stock is owned by hedge funds and other institutional investors.

WARNING: This article was originally reported by American Banking News and is the property of of American Banking News. If you are viewing this article on another site, it was copied illegally and republished in violation of United States & international copyright and trademark laws. The legal version of this article can be read at https://www.americanbankingnews.com/2017/12/05/audentes-therapeutics-bold-receives-new-coverage-from-analysts-at-bmo-capital-markets.html.

About Audentes Therapeutics

Audentes Therapeutics, Inc is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).

Analyst Recommendations for Audentes Therapeutics (NASDAQ:BOLD)

Receive News & Ratings for Audentes Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.